- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06047379
Seguridad y eficacia de NEO212 en pacientes con astrocitoma IDH mutante, glioblastoma IDH de tipo salvaje o metástasis cerebral
Un estudio abierto de fase 1/2 de búsqueda de dosis, seguridad y eficacia de NEO212 oral en pacientes con astrocitoma IDH mutante, glioblastoma IDH de tipo salvaje o metástasis cerebral no controlada en pacientes con tumores sólidos seleccionados.
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain.
The study will have three phases, Phase 1, Phase 2a and Phase 2b.
Descripción general del estudio
Estado
Condiciones
- Melanoma
- Carcinoma de células renales
- Cáncer de cuello uterino
- Cáncer de pulmón de células pequeñas
- Cáncer gástrico
- Cáncer colonrectal
- Cáncer de esófago
- Cáncer de pulmón de células no pequeñas
- Carcinoma de células escamosas de cabeza y cuello
- Carcinoma de células escamosas de esófago
- Carcinoma urotelial
- Carcinoma de células de Merkel
- Adenocarcinoma de la unión gastroesofágica
- Metástasis Cerebral, Adulto
- Carcinoma de células escamosas
- Glioblastoma, tipo salvaje IDH
- Astrocitoma difuso, mutante IDH
- Cáncer colorrectal con alteración en la vía reparadora
- Inestabilidad de microsatélites: tumor maligno sólido alto
- Reparación de desajustes de tumor maligno sólido deficiente
- Inestabilidad de microsatélites: cáncer colorrectal elevado
Descripción detallada
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled brain metastasis. The study will have three phases, Phase 1, Phase 2a and Phase 2b.
Phase 1 is a standard cohort dose escalation 3+3 design with a modified Fibonacci dose escalation used to determine the maximum tolerated dose to select a recommended Phase 2 dose (RP2D) of NEO212 for Phase 2a and Phase 2b. The initial dose of NEO212 will be 170 mg and the dose will increase in successive cohorts (220, 400, 610, 810, and 1,000 mg) until a MTD is reached and a RP2D is selected. There will be up to 42 patients enrolled in Phase 1. In the event two DLTs are experienced in any cohort, a dose de- escalation cohort will be followed (with half of the dose increase from the previous cohort) to determine the MTD/RP2D.
Phase 2a is a safety run-in study with a standard 3+3 design used to confirm the safety of the MTD/RP2D of NEO212 when given in combination with select SOC regimens for patients with uncontrolled metastases to the brain. There will be up to 12 patients enrolled into each combination regimen to confirm safety. One dose below the NEO212 MTD/RP2D Cohort Dose will be administered as a starting dose to establish safety (3+3), before moving to Phase 2b with the MTD/RP2D (3+3). In the event that two DLTs are experienced for patients receiving the MTD/RP2D in combination with SOC, the dose de-escalation cohort will be expanded to determine the MTD for a newly established Phase 2b Treatment Group.
Phase 2b is a dose expansion study to assess efficacy of NEO212 alone, at the MTD/RP2D in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype as a single Treatment Group. A second Treatment Group to study the MTD/RP2D of NEO212 in combination with select SOC regimens in patients with solid tumors and uncontrolled metastases to the brain established in Phase 2a will be evaluated. Phase 2b will be initiated for patients with Astrocytoma IDH-mutant or Glioblastoma IDH-wildtype alongside Phase 2a. There will be up to 28 patients enrolled to have 27 evaluable patients enrolled in each Phase 2b Treatment Group.
For all phases of the study, NEO212 will be self-administered daily for days 1-5 of a 28- day treatment cycle.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Chloe Richmond
- Número de teléfono: 224 218 2408
- Correo electrónico: chloe@anovaevidence.com
Copia de seguridad de contactos de estudio
- Nombre: Christopher Beardmore
- Número de teléfono: 224 218 2408
- Correo electrónico: chris@anovaevidence.com
Ubicaciones de estudio
-
-
California
-
Beverly Hills, California, Estados Unidos, 90212
- Reclutamiento
- Precision NextGen Oncology
-
Investigador principal:
- Kamlesh Sankhala, MD
-
Contacto:
- Jing Liu, MD MA
- Número de teléfono: (424) 777-0708
- Correo electrónico: JingL@nextgenonc.com
-
Glendale, California, Estados Unidos, 91203
- Reclutamiento
- OPN Healthcare, Inc
-
Investigador principal:
- Vu Phan, MD
-
Contacto:
- Heather Lyon
- Correo electrónico: heatherl@opnhc.com
-
Los Angeles, California, Estados Unidos, 90033
- Reclutamiento
- University of Southern California
-
Investigador principal:
- Frances Chow, MD
-
Contacto:
- Sandy Tran
- Número de teléfono: (323) 865-3980
- Correo electrónico: Sandy.Tran@med.usc.edu
-
-
Florida
-
Boynton Beach, Florida, Estados Unidos, 33426
- Reclutamiento
- MDR Core Network
-
Investigador principal:
- Robert Levin, MD
-
Contacto:
- Ismaray Hernandez
- Correo electrónico: ismaray@mdrcore.com
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 21111
- Reclutamiento
- Tufts Medical Center
-
Contacto:
- Christian Lawlor
- Correo electrónico: Christian.Lawlor@tuftsmedicine.org
-
Contacto:
- Soma Sengupta, MD
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Reclutamiento
- Vanderbilt University Medical Center
-
Investigador principal:
- Alexander Mohler, MD
-
Contacto:
- Amanda Nolen
- Correo electrónico: amanda.nolen@vumc.org
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75246
- Reclutamiento
- Baylor, Scott and White Research Institute
-
Contacto:
- Tarah Satterfield
- Correo electrónico: Tarah.Satterfield@bswhealth.org
-
Investigador principal:
- Divya Mella, MD
-
-
Washington
-
Tacoma, Washington, Estados Unidos, 98405
- Reclutamiento
- Northwest Medical Specialties
-
Investigador principal:
- Jorge Chaves, MD
-
Contacto:
- Sheila Marsh
- Número de teléfono: 253-380-8173
- Correo electrónico: smarsh@nwmsonline.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Patient must be ≥ 18yrs of age.
-
Patient must have the ability to understand, and the willingness to sign, a written informed consent form.
-
Patient has been on a stable or decreasing dose of steroids for at least five days prior to the date of informed consent.
-
Any toxicity from prior therapy must be resolved or at maximum Grade 1 prior to initiation of NEO212.
-
If progression of disease occurs within 90 days or conformal radiation, the progression/recurrence must be outside of the radiation field or proven by biopsy/resection.
-
Patient with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype must have a Karnofsky Performance Status (KPS) of ≥ 60.
-
Patient with select solid tumors must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
-
Patient must have an expected survival or at least three months.
-
Patient must have a baseline MRI of the brain with gadolinium within 14 days of administration of NEO212.
-
Patient with select solid tumors must have a baseline CT scan with IV contrast and oral contrast of neck, chest, abdomen and pelvis within 14 days of administration of NEO212.
-
Patients must be able to comply with all study assessments.
-
If patient suffers from seizures (s)he must be controlled on a stable dose of anti-epileptics for 14-days prior to the date of informed consent.
-
Patient must have adequate organ and marrow function as follows:
- Absolute neutrophil count ≥ 1,500/microliter
- Platelets ≥ 100,000/microliter
- Total bilirubin within normal institutional limits
- AST (SGOT) / ALT (SPGT) ≤ 2.5 x institutional upper limit of normal
- Creatinine clearance (CrCl) of >60 mL/min (using the Cockcroft-Gault formula or 24- hour urine collection).
-
Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first dose of NEO212, for the duration of study participation, and for 90 days following completion of therapy.
A female of child-bearing potential is any women (regardless of sexual orientation, not having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has not had menses at any time in the preceding 12 consecutive months).
- A negative serum pregnancy test will be required of all female patients of child-bearing potential within seven days prior to the receipt of NEO212.
- A serum pregnancy test will be repeated immediately if pregnancy is suspected.
Phase 1: (dose escalation)
-
Patient must:
- have radiographically confirmed Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype following previous radiation therapy or treatment with temozolomide and radiation, or
- have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
-
Patients receiving prior systemic therapy must have a minimum wash-out period (defined as the period prior to receipt of the first dose of NEO212) of:
- 28 days or 5 half-lives (whichever is shorter) elapsed from the administration from any experimental agent;
- 2 weeks from administration of immunotherapies;
- 28 days from administration of cytotoxic agents; and
- 7 days from administration of non-cytotoxic agents (interferon, tamoxifen, thalidomide, cis-retinoic acid, and herbal medicine).
NOTE: No washout is necessary for alternating electrical fields.
Phase 2a: (safety run-in)
- Patient must have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
- Patients receiving prior systemic therapy must be receiving one of the protocol approved Standard of Care (SOC) regimens.
- Patient must have measurable/evaluable CNS disease per RANO or RANO-BM criteria.
- Patient must have measurable/evaluable systemic disease per RECIST v1.1 criteria.
Phase 2b: (efficacy)
-
Patient must:
- have radiographically confirmed Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype following previous radiation therapy or treatment with temozolomide and radiation, or
- have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
-
Patients receiving prior systemic therapy must be receiving one of the protocol approved Standard of Care (SOC) regimens.
-
Patient must have measurable/evaluable CNS disease per RANO or RANO-BM criteria
-
Patient with select solid tumors must have measurable/evaluable systemic disease per RECIST v1.1 criteria.
-
Creatinine clearance (CrCl) of >60 mL/min (using the Cockcroft-Gault formula or 24-hour urine collection). Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first dose of NEO212, for the duration of study participation, and for 90 days following completion of therapy.
Exclusion Criteria: (all Phases)
- Patient in Phase 1 concurrently receiving any other antitumor therapy.
- Patient in Phase 2a or 2b who is concurrently receiving any SOC therapy not listed in Appendix 1.
- Patients with metastases to the spinal cord parenchyma.
- Patients with metastases to the meninges.
- Patient has received stereotactic or highly conformal radiotherapy to CNS lesions within 2 weeks before receipt of NEO212.
- Patient with history of known leptomeningeal involvement.
- Patient has prior history or new diagnosis of secondary cancer within five years prior to the date of informed consent, except for basal cell carcinoma or squamous cell carcinoma of the skin.
- Patient has a corrected QT interval (using Fridericia's correction formula) (QTcF) of >470 msec, a history of additional risk factors for TdP (e.g. heart failure, hypokalemia), and/or the use of concomitant medications that prolong QT/QTc interval.
- Patient had surgery within 7 days prior to the date of informed consent.
- Patient has not recovered to Grade 1 from treatment related adverse events due to chemotherapy, immunotherapy, or radiation therapy.
- Patient had prior treatment with perillyl alcohol.
- Patient has a history of allergic reactions attributed to perillyl alcohol.
- Patients in Phase 2b with Astrocytoma IDH-mutant, or Glioblastoma IDH-wildtype who have had more than one recurrence or progression of his/her primary CNS tumor(s).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Phase 2a Safety Run-In - NEO212 and Ipilimumab
- Unresectable or metastatic melanoma with uncontrolled metastases to the brain. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Ipilimumab - 3 mg/kg administered IV over 90 minutes every 3 weeks for a maximum of 3 doses per package insert. |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Otros nombres:
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
Otros nombres:
|
|
Experimental: Phase 2a Safety Run-In - NEO212 and Pembrolizumab
The following primary cancers with uncontrolled metrastases to the brain:
NEO212 - Same as Arm 1. Pembrolizumab - 200 mg administered every 3 weeks per package insert. |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Otros nombres:
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
Otros nombres:
|
|
Experimental: Phase 2a Safety Run-In - NEO212 and Nivolumab
The following primary cancers with uncontrolled metrastases to the brain:
NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Nivolumab - 240 mg administered every 2 weeks per package insert |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Otros nombres:
Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
Otros nombres:
|
|
Experimental: Phase 2a Safety Run-In - NEO212 and Stivarga (Regorafenib)
- Colorectal cancer (CRC) with uncontrolled metastases to the brain who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anU-EGFR therapy. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Stivarga - 160 mg orally, once daily for the first 21 days of each 28-day cycle per package insert |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Otros nombres:
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
Otros nombres:
|
|
Experimental: Phase 2a Safety Run-In - NEO212 and CarbolaUn (ParaplaUn) + Paclitaxel (Taxol)
- Colorectal cancer (CRC) with uncontrolled metastases to the brain. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. Carboplatin - 300 mg/m2 IV on day 1 every 4 weeks for 6 cycles per package insert. Paclitaxel - 135mg/m2 IV administered over 24 hours, every 3 weeks per package insert. |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Otros nombres:
Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
Otros nombres:
Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
Otros nombres:
|
|
Experimental: Phase 2a Safety Run-In - NEO212 and FOLFIRI (Zaltrap) + Bevacizumab (Avastin)
- Metastatic colorectal cancer (mCRC) with uncontrolled metastases to the brain, that is resistant to or has progressed following an oxaliplatin-containing regimen NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. FOLFIRI - 4 mg/kg aIV over 1 hour every 2 weeks. Bevacizumab - 10 mg/kg IV every 2 weeks. |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Otros nombres:
FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs: FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
Otros nombres:
Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
Otros nombres:
|
|
Experimental: Phase 2b efficacy - NEO212 for Astrocytoma IDH-mutant and Glioblastoma IDH-wildtype
Patients receiving NEO212 alone for treatment of Astrocytoma IDH-mutant and Glioblastoma IDH-wildtype. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Otros nombres:
|
|
Experimental: Phase 2b efficacy - NEO212 & SOC for Uncontrolled Metastases to the Brain
Patients receiving NEO212 in combination with select standard of care treatments for treatment of uncontrolled metastases to the brain. NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules. SOC treatments established to be safe in Phase 2a of the study will be used in this arm of Phase 2b. |
NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
Otros nombres:
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
Otros nombres:
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
Otros nombres:
Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
Otros nombres:
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
Otros nombres:
Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
Otros nombres:
Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
Otros nombres:
FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs: FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
Otros nombres:
Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain
Periodo de tiempo: 6 months
|
As determined by incidence and severity of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0 |
6 months
|
|
Phase 1: Identify the maximum tolerated dose (MTD) of NEO212
Periodo de tiempo: 6 months
|
Maximum Tolerated Dose of NEO212 as determined by the dose escalation rules. |
6 months
|
|
Phase 1: Determine the recommended Phase 2 dose (RP2D) of NEO212
Periodo de tiempo: 6 months
|
Determine the recommended Phase 2 dose (RP2D) of NEO212 |
6 months
|
|
Phase 2a: Assess the safety and tolerability of orally administered NEO212 in combination with select SOC regimens following a standard 3+3 design in patients with select solid tumors with uncontrolled metastases to the brain
Periodo de tiempo: 6 months
|
Determined by incidence and severity of adverse events determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0). |
6 months
|
|
Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype.
Periodo de tiempo: 6 months
|
Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype. |
6 months
|
|
Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors with uncontrolled metastases to the brain.
Periodo de tiempo: 6 months
|
Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors (see Appendix 2) with uncontrolled metastases to the brain. |
6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Tom Chen, MD, PhD, NeOnc Technologies
- Director de estudio: Josh Neman, PhD, NeOnc Technologies Holdings, Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades intestinales
- Infecciones
- Enfermedades virales
- Enfermedades de las vías respiratorias
- Neoplasias por tipo histológico
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Estómago
- Neoplasias Intestinales
- Enfermedades Rectales
- Enfermedades uterinas
- Enfermedades Genitales Femeninas
- Enfermedades pulmonares
- Neoplasias de Cabeza y Cuello
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Enfermedades del Colon
- Infecciones por virus de ADN
- Enfermedades esofágicas
- Neoplasias Pulmonares
- Neoplasias Genitales Femeninas
- Enfermedades de la piel
- Neoplasias Urológicas
- Carcinoma
- Neoplasias De Células Escamosas
- Enfermedades del cuello uterino
- Glioma
- Neoplasias Neuroepiteliales
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Neoplasias del Sistema Nervioso
- Neoplasias Renales
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Neoplasias Uterinas
- Tumores neuroendocrinos
- Infecciones por virus tumorales
- Nevos y Melanomas
- Neoplasias De La Piel
- Infecciones por poliomavirus
- Carcinoma Neuroendocrino
- Enfermedades de la piel y del tejido conectivo
- Carcinoma de células escamosas de cabeza y cuello
- Carcinoma de células escamosas de esófago
- Neoplasias de Estómago
- Neoplasias colorrectales
- Neoplasias Esofágicas
- Carcinoma De Células Escamosas
- Glioblastoma
- Carcinoma De Célula Renal
- Carcinoma de pulmón de células no pequeñas
- Neoplasias del cuello uterino
- Carcinoma de pulmón de células pequeñas
- Melanoma
- Neoplasias Cerebrales
- Carcinoma De Células De Transición
- Astrocitoma
- Neoplasias del Sistema Nervioso Central
- Carcinoma De Células De Merkel
- Aminoácidos, péptidos y proteínas
- Proteínas
- Químicos orgánicos
- Hidrocarburos
- Cicloparafinas
- Hidrocarburos, alicíclicos
- Hidrocarburos, cíclico
- Terpenos
- Anticuerpos, monoclonales, humanizados
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Complejos de coordinación
- Taxaides
- Ciclodecanos
- Diterpenos
- Nivolumab
- Bevacizumab
- Ipilimumab
- Carboplatino
- Paclitaxel
- pembrolizumab
- regorafenib
- afliberceptible
- Protocolo IFL
- NEO212
Otros números de identificación del estudio
- NEO212-01
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .